摘要
Roseburia菌属是一种专性革兰阳性厌氧菌,能产生丁酸盐,已被证实与多种感染、代谢、免疫、神经系统、消化系统疾病有关。本文介绍了多种针对Roseburia的益生元,并评估了Roseburia作为益生菌药物开发的潜力。Roseburia在肠易激综合征、炎症性肠病及结直肠癌患者肠道中的丰度有显著变化,提示了其在肠道疾病诊断中的潜在作用。补充Roseburia可能通过调节肠道免疫和屏障功能治疗肠道疾病。
The genus Roseburia consists of obligate Gram-positive anaerobic bacteria that produces butyrate in the colon.Roseburia spp.has been shown to be associated with various infections,metabolic,immune,nervous system,and gastrointestinal diseases.This review introduces several prebiotics targeting Roseburia spp.,and evaluates the potential of Roseburia spp.as a probiotic drug development.Patients with irritable bowel syndrome,inflammatory bowel disease,and colorectal cancer exhibit significant changes in Roseburia spp.abundance,which reveals the potential diagnostic role of Roseburia spp.in human colonic.Modulations targeting Roseburia spp.may contribute to gastrointestinal diseases by regulating intestinal immunity and barrier function.
作者
冯泽宇
蔡彬
朱欢欢
FENG Zeyu;CAI Bin;ZHU Huanhuan(Department of Anorectal Surgery,Wuxi Traditional Chinese Medicine Hospital,Jiangsu 214071)
出处
《南通大学学报(医学版)》
2025年第6期570-574,共5页
Journal of Nantong University(Medical sciences)
基金
国家自然科学基金资助项目(82405395,82205110)
南京中医药大学自然科学基金资助项目(XZR2021070)
无锡市卫生健康委中青年拔尖人才资助计划(BJ2023067)。
